# ![@BioStocks Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::112872946.png) @BioStocks Bio Stocks™

Bio Stocks™ posts on X about $lly, data, $guts, $nvo the most. They currently have [------] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.

### Engagements: [-----] [#](/creator/twitter::112872946/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::112872946/c:line/m:interactions.svg)

- [--] Week [-------] -49%
- [--] Month [-------] -2.50%
- [--] Months [---------] +67%
- [--] Year [---------] +29%

### Mentions: [--] [#](/creator/twitter::112872946/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::112872946/c:line/m:posts_active.svg)

- [--] Week [---] -15%
- [--] Month [---] +4.30%
- [--] Months [-----] +86%
- [--] Year [-----] +64%

### Followers: [------] [#](/creator/twitter::112872946/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::112872946/c:line/m:followers.svg)

- [--] Week [------] -0.03%
- [--] Month [------] +0.31%
- [--] Months [------] +3.30%
- [--] Year [------] +6.10%

### CreatorRank: [-------] [#](/creator/twitter::112872946/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::112872946/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[finance](/list/finance)  100% [stocks](/list/stocks)  79.59% [cryptocurrencies](/list/cryptocurrencies)  6.12% [technology brands](/list/technology-brands)  4.08% [vc firms](/list/vc-firms)  #82 [countries](/list/countries)  1.36% [currencies](/list/currencies)  1.36% [financial services](/list/financial-services)  0.68% [exchanges](/list/exchanges)  0.68%

**Social topic influence**
[$lly](/topic/$lly) #12, [data](/topic/data) 6.12%, [$guts](/topic/$guts) 6.12%, [$nvo](/topic/$nvo) #20, [$prax](/topic/$prax) 5.44%, [$175m](/topic/$175m) 4.08%, [$lucd](/topic/$lucd) 3.4%, [the first](/topic/the-first) 3.4%, [$hims](/topic/$hims) #415, [$rvmd](/topic/$rvmd) 3.4%

**Top accounts mentioned or mentioned by**
[@wallstreet_dawg](/creator/undefined) [@biopharmiq](/creator/undefined) [@octopusking77](/creator/undefined) [@nexttradex](/creator/undefined) [@biomaven](/creator/undefined) [@amaymd](/creator/undefined) [@joserestonva](/creator/undefined) [@grok](/creator/undefined) [@pnani456](/creator/undefined) [@phantomfrith](/creator/undefined) [@michaelrose102](/creator/undefined) [@rdglinvestors](/creator/undefined) [@jason_prat06](/creator/undefined) [@jessiechimni](/creator/undefined) [@drrichjlaw](/creator/undefined) [@avidresearch](/creator/undefined) [@varro_analytics](/creator/undefined) [@bambossie81](/creator/undefined) [@bioinvesting5](/creator/undefined) [@zequalizer](/creator/undefined)

**Top assets mentioned**
[Eli Lilly and Company (LLY)](/topic/$lly) [Fractyl Health, Inc. (GUTS)](/topic/$guts) [Novo-Nordisk (NVO)](/topic/$nvo) [Praxis Precision Medicines, Inc. (PRAX)](/topic/$prax) [Lucid Diagnostics Inc. (LUCD)](/topic/$lucd) [Hims & Hers Health, Inc. (HIMS)](/topic/$hims) [Revolution Medicines, Inc. (RVMD)](/topic/$rvmd) [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [Ocular Therapeutix, Inc. (OCUL)](/topic/$ocul) [Merck & Co., Inc. (MRK)](/topic/$mrk) [BridgeBio Pharma, Inc. Common Stock (BBIO)](/topic/$bbio) [Century Therapeutics, Inc. (IPSC)](/topic/$ipsc) [LYRA (LYRA)](/topic/$lyra) [Biogen Inc (BIIB)](/topic/$biib) [Royalty Pharma plc (RPRX)](/topic/$rprx) [4D Molecular Therapeutics Inc. (FDMT)](/topic/$fdmt) [Unicycive Therapeutics, Inc. (UNCY)](/topic/$uncy) [GoodRx Holdings, Inc. (GDRX)](/topic/$gdrx) [Instil Bio, Inc. (TIL)](/topic/$til) [Alumis Inc. (ALMS)](/topic/$alms) [Invivyd, Inc. (IVVD)](/topic/$ivvd) [Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt) [Arrowhead Research Corporation (ARWR)](/topic/$arwr) [Tempus AI, Inc. (TEM)](/topic/$tem) [AstraZeneca PLC (AZN)](/topic/$azn) [Exelixis Inc (EXEL)](/topic/$exel) [Amylyx Pharmaceuticals, Inc. (AMLX)](/topic/$amlx) [Johnson & Johnson (JNJ)](/topic/$jnj) [Lexeo Therapeutics, Inc (LXEO)](/topic/$lxeo) [Liquity BOLD (BOLD)](/topic/$bold) [Regeneron Pharmaceuticals Inc (REGN)](/topic/$regn) [United Therapeutics, Corp. (UTHR)](/topic/$uthr) [Evommune, Inc. (EVMN)](/topic/$evmn) [Synthetify (SNY)](/topic/$sny) [Cullinan Management, Inc. (CGEM)](/topic/$cgem) [C4 Therapeutics, Inc (CCCC)](/topic/$cccc) [Pharvaris, B.V. (PHVS)](/topic/$phvs) [Denali Therapeutics Inc. Common Stock (DNLI)](/topic/$dnli) [Mainz Biomed N.V. (MYNZ)](/topic/$mynz) [Dyne Therapeutics, Inc. (DYN)](/topic/dyne-therapeutics) [Kymera Therapeutics, Inc. (KYMR)](/topic/$kymr) [Olema Pharmaceuticals, Inc. (OLMA)](/topic/$olma) [Indivior PLC Ordinary Shares (INDV)](/topic/$indv) [ARS Pharmaceuticals, Inc. (SPRY)](/topic/$spry) [Context Therapeutics Inc. (CNTX)](/topic/$cntx) [Zenas BioPharma, Inc. (ZBIO)](/topic/$zbio) [Inari Medical, Inc. (NARI)](/topic/$nari) [Alcon Inc. Ordinary Shares (ALC)](/topic/$alc) [Harmony Biosciences Holdings, Inc. (HRMY)](/topic/$hrmy)
### Top Social Posts
Top posts by engagements in the last [--] hours

"$INMB Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimers Disease https://www.inmunebio.com/index.php/newsroom/2026-news/muneionnounceslignmentonntegratedhase2b320260212040512 https://www.inmunebio.com/index.php/newsroom/2026-news/muneionnounceslignmentonntegratedhase2b320260212040512"  
[X Link](https://x.com/BioStocks/status/2021919159840608547)  2026-02-12T12:07Z 71.3K followers, [----] engagements


"$IPSC Presents Interim Results from Phase [--] ELiPSE-1 Study at #ASCO24 https://investors.centurytx.com/news-releases/news-release-details/century-therapeutics-presents-interim-results-phase-1-elipse-1 https://investors.centurytx.com/news-releases/news-release-details/century-therapeutics-presents-interim-results-phase-1-elipse-1"  
[X Link](https://x.com/BioStocks/status/1797584587583033512)  2024-06-03T11:02Z 71.3K followers, [----] engagements


"$CGEM Receives FDA Fast Track Designation for CLN-049 a Novel FLT3xCD3 T Cell Engager in Relapsed/Refractory Acute Myeloid Leukemia"  
[X Link](https://x.com/BioStocks/status/1995463585250635787)  2025-12-01T12:02Z 71.3K followers, [----] engagements


"$CCCC initiated with a Buy at TD Cowen"  
[X Link](https://x.com/BioStocks/status/1995818246751359476)  2025-12-02T11:32Z 71.3K followers, [----] engagements


"$PHVS Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks"  
[X Link](https://x.com/BioStocks/status/1996197009720770816)  2025-12-03T12:37Z 71.3K followers, [----] engagements


"$DNLI and $RPRX Announce $275M Royalty Funding Agreement"  
[X Link](https://x.com/BioStocks/status/1996550431926059232)  2025-12-04T12:01Z 71.3K followers, [----] engagements


"$MNOV $300M shelf $LUCD $175M shelf $MYNZ $150M shelf $RZLT shelf"  
[X Link](https://x.com/BioStocks/status/1997162383962526066)  2025-12-06T04:33Z 71.3K followers, [----] engagements


"$DYN Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in DMD https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-positive-topline-results-phase-12 https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-positive-topline-results-phase-12"  
[X Link](https://x.com/BioStocks/status/1997993355289272683)  2025-12-08T11:35Z 71.3K followers, 11.1K engagements


"$KYMR Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621 a First-in-Class Oral STAT6 Degrader in Patients with Moderate to Severe Atopic Dermatitis https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-positive-results-broaden-phase-1b https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-positive-results-broaden-phase-1b"  
[X Link](https://x.com/BioStocks/status/1998000070168654276)  2025-12-08T12:01Z 71.3K followers, 26.1K engagements


"$LUCD Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection. https://www.prnewswire.com/news-releases/lucid-diagnostics-announces-positive-data-from-the-largest-reported-real-world-experience-of-esophageal-precancer-detection-302636532.html https://www.prnewswire.com/news-releases/lucid-diagnostics-announces-positive-data-from-the-largest-reported-real-world-experience-of-esophageal-precancer-detection-302636532.html"  
[X Link](https://x.com/BioStocks/status/1998377596573381107)  2025-12-09T13:02Z 71.3K followers, 12.1K engagements


"$ARGX discontinues Phase [--] UplighTED studies evaluating efgartigimod subcutaneous in adults with moderate to severe thyroid eye disease https://ca.finance.yahoo.com/news/argenx-provides-uplighted-studies-efgartigimod-060000833.html https://ca.finance.yahoo.com/news/argenx-provides-uplighted-studies-efgartigimod-060000833.html"  
[X Link](https://x.com/BioStocks/status/2000524040247579093)  2025-12-15T11:11Z 71.3K followers, 10.3K engagements


"$FDMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase [--] Clinical Trial in Cystic Fibrosis Lung Disease https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-announces-positive-interim-clinical-data-4d-710-aerow-phase https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-announces-positive-interim-clinical-data-4d-710-aerow-phase"  
[X Link](https://x.com/BioStocks/status/2001261656459120644)  2025-12-17T12:02Z 71.3K followers, [----] engagements


"Six Individuals Charged in $41 Million Insider Trading and Market Manipulation Scheme Involving Biotech Companies. $OLMA $OPNT $INDV"  
[X Link](https://x.com/BioStocks/status/2005315305858347101)  2025-12-28T16:30Z 71.3K followers, 11.9K engagements


"$UNCY resubmits Oxylanthanum Carbonate (OLC) NDA"  
[X Link](https://x.com/BioStocks/status/2005612788190941602)  2025-12-29T12:12Z 71.3K followers, [----] engagements


"$SPRY neffy Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)"  
[X Link](https://x.com/BioStocks/status/2005625340690112705)  2025-12-29T13:01Z 71.3K followers, [----] engagements


"$RPRX Acquires Remaining Royalty Interest in Roches Evrysdi for $240M and Potential Milestones"  
[X Link](https://x.com/BioStocks/status/2005785509407100970)  2025-12-29T23:38Z 71.3K followers, [----] engagements


"$CYBN launches $100M ATM offering. $HELP"  
[X Link](https://x.com/BioStocks/status/2006181952345239777)  2025-12-31T01:53Z 71.3K followers, [----] engagements


"$GUTS Randomized 6-month data from the REMAIN-1 Midpoint Cohort expected in late Jan Topline 6-month data from the REMAIN-1 Pivotal Cohort and potential PMA submission expected in 2H'26 Received $23M from exercises of Tranche A warrants with cash runway into early 2027"  
[X Link](https://x.com/BioStocks/status/2008163102966026394)  2026-01-05T13:06Z 71.3K followers, [----] engagements


"$CNTX #biopick2026"  
[X Link](https://x.com/BioStocks/status/2008163502125699510)  2026-01-05T13:07Z 71.3K followers, [----] engagements


"$GDRX Now Offers Novo's Cash Price for the Launch of the Wegovy Pill. $HIMS"  
[X Link](https://x.com/BioStocks/status/2008164017445970186)  2026-01-05T13:09Z 71.3K followers, [----] engagements


"$ZBIO 'Positive' Results from Phase [--] INDIGO Registrational Trial"  
[X Link](https://x.com/BioStocks/status/2008168236617977897)  2026-01-05T13:26Z 71.3K followers, 14.6K engagements


"$TIL Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco"  
[X Link](https://x.com/BioStocks/status/2008509117556814220)  2026-01-06T12:01Z 71.3K followers, 12.6K engagements


"$GUTS Appoints Lara Smith Weber (ex $NARI) as CFO to Support Commercial-Stage Preparedness"  
[X Link](https://x.com/BioStocks/status/2008510756271329424)  2026-01-06T12:07Z 71.3K followers, 11K engagements


"$ALMS $175M offering $DRUG $100M offering $PRAX offering"  
[X Link](https://x.com/BioStocks/status/2008672122651189690)  2026-01-06T22:48Z 71.3K followers, [----] engagements


"$ALC Alcon Terminates Agreement to Acquire STAAR Surgical. $STAA"  
[X Link](https://x.com/BioStocks/status/2008707433682923809)  2026-01-07T01:09Z 71.3K followers, [----] engagements


"$IVVD Preliminary Q4 [----] PEMGARDA net product revenue of $17.2M representing 25% growth YoY. Preliminary ending [----] cash and equivalents of $226.7M Topline data from DECLARATION Phase [--] pivotal trial of vaccine-alternative antibody VYD2311 to prevent COVID expected mid-2026"  
[X Link](https://x.com/BioStocks/status/2009234779523481700)  2026-01-08T12:04Z 71.3K followers, [----] engagements


"$LYRA to suspend further development of LYR-210 the Companys lead product candidate for the treatment of chronic rhinosinusitis (CRS). $LYRA halt $LYRA halt"  
[X Link](https://x.com/BioStocks/status/2010683700770410703)  2026-01-12T12:02Z 71.3K followers, 14.5K engagements


"$PRAX Wedbush maintains an Underperform PT $95"  
[X Link](https://x.com/BioStocks/status/2010686431765643706)  2026-01-12T12:12Z 71.3K followers, [----] engagements


"$PRAX two NDA submissions expected by mid-February [----] for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs. $1.5 billion in pro forma cash and investments. Combined peak revenue estimates for the four late-stage assets are expected to exceed $20 billion"  
[X Link](https://x.com/BioStocks/status/2010699712148418754)  2026-01-12T13:05Z 71.3K followers, [----] engagements


"$HRMY WAKIX FY'25 Preliminary Net Revenue of $868M. FY'26 WAKIX Net Revenue Guidance of $1.0 $1.04 Billion on Track for Blockbuster Status in Narcolepsy"  
[X Link](https://x.com/BioStocks/status/2010700185161093423)  2026-01-12T13:07Z 71.3K followers, [----] engagements


"$LYRA $LYRA to suspend further development of LYR-210 the Companys lead product candidate for the treatment of chronic rhinosinusitis (CRS). $LYRA to suspend further development of LYR-210 the Companys lead product candidate for the treatment of chronic rhinosinusitis (CRS)"  
[X Link](https://x.com/BioStocks/status/2010705400069316687)  2026-01-12T13:28Z 71.3K followers, [----] engagements


"$IVVD Announces Plan for Phase [--] Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 https://investors.invivyd.com/news-releases/news-release-details/invivyd-and-spear-study-group-announce-plan-phase-2-study https://investors.invivyd.com/news-releases/news-release-details/invivyd-and-spear-study-group-announce-plan-phase-2-study"  
[X Link](https://x.com/BioStocks/status/2013585855076593971)  2026-01-20T12:14Z 71.3K followers, [----] engagements


"$LUCD Awarded U.S. Department of Veterans Affairs Contract for EsoGuard. $PAVM The contract includes pre-negotiated pricing for EsoGuard that matches the established Medicare payment rate determined by the CMS enabling VA hospitals and healthcare facilities nationwide to access EsoGuard through a single national VA procurement framework. https://www.prnewswire.com/news-releases/lucid-diagnostics-awarded-us-department-of-veterans-affairs-contract-for-esoguard-302666707.html"  
[X Link](https://x.com/BioStocks/status/2013963141118370198)  2026-01-21T13:13Z 71.3K followers, 10.9K engagements


"@NextTradeX Hardly any movement in $LUCD. weird"  
[X Link](https://x.com/BioStocks/status/2013966454954017056)  2026-01-21T13:26Z 71.3K followers, [----] engagements


"$LUCD has a $175M shelf ready to go $LUCD Big contract. No position for me anymore though. $PAVM being an ultra-low float is running hard while $LUCD has not moved much on this news yet. I suspect a secondary soon $LUCD Big contract. No position for me anymore though. $PAVM being an ultra-low float is running hard while $LUCD has not moved much on this news yet. I suspect a secondary soon"  
[X Link](https://x.com/BioStocks/status/2013979802324042156)  2026-01-21T14:19Z 71.3K followers, [----] engagements


"$ERAS prices $225M offering. 22.5M shares at $10/share"  
[X Link](https://x.com/BioStocks/status/2014156174468186293)  2026-01-22T02:00Z 71.3K followers, 11.1K engagements


"$BIIB FDA Accepts LEQEMBI IQLIK sNDA as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease under Priority Review. $ESAIY PDUFA 05/24/26 https://investors.biogen.com/news-releases/news-release-details/fda-accepts-leqembir-iqliktm-lecanemab-irmb-supplemental https://investors.biogen.com/news-releases/news-release-details/fda-accepts-leqembir-iqliktm-lecanemab-irmb-supplemental"  
[X Link](https://x.com/BioStocks/status/2015736557777420711)  2026-01-26T10:40Z 71.3K followers, [----] engagements


"$RHHBY Roche announces positive Phase [--] results for its dual GLP-1/GIP receptor agonist. $LLY $NVO Weekly injections of CT-388 (titrated up to [--] mg) resulted in significant and clinically meaningful placebo-adjusted weight loss of 22.5% (p 0.001) https://www.globenewswire.com/news-release/2026/01/27/3226074/0/en/Ad-hoc-announcement-pursuant-to-Art-53-LR-Roche-announces-positive-Phase-II-results-for-its-dual-GLP-1-GIP-receptor-agonist-CT-388-in-people-living-with-obesity.html"  
[X Link](https://x.com/BioStocks/status/2016102635057906073)  2026-01-27T10:55Z 71.3K followers, 11.4K engagements


"$ARWR Initiates Phase 1/2a Study of ARO-DIMER-PA the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia"  
[X Link](https://x.com/BioStocks/status/2016127764370276722)  2026-01-27T12:34Z 71.3K followers, [----] engagements


"$CRDF $CRDF Announces Positive Update from its Randomized Phase [--] Trial of Onvansertib in First-line RAS-mutated mCRC https://t.co/Adwf7iCImx $CRDF Announces Positive Update from its Randomized Phase [--] Trial of Onvansertib in First-line RAS-mutated mCRC https://t.co/Adwf7iCImx"  
[X Link](https://x.com/BioStocks/status/2016129512157667678)  2026-01-27T12:41Z 71.3K followers, [----] engagements


"$TEM Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers https://www.businesswire.com/news/home/20260127324978/en/Tempus-Reveals-Its-AI-Driven-IPS-Test-More-Accurately-Predicts-Immunotherapy-Benefit-Compared-to-Conventional-Biomarkers https://www.businesswire.com/news/home/20260127324978/en/Tempus-Reveals-Its-AI-Driven-IPS-Test-More-Accurately-Predicts-Immunotherapy-Benefit-Compared-to-Conventional-Biomarkers"  
[X Link](https://x.com/BioStocks/status/2016142442253189235)  2026-01-27T13:33Z 71.4K followers, [----] engagements


"$PRAX PT raised from $450 to $1200 at Piper 💥"  
[X Link](https://x.com/BioStocks/status/2016514606827511890)  2026-01-28T14:12Z 71.3K followers, 10.8K engagements


"$AZN AstraZeneca to invest $15 billion in China to pioneer the next-generation of innovative medicines. $XBI https://news.cision.com/se/astrazeneca/r/astrazeneca-plans-to-invest--15-billion-in-china-through-2030-to-pioneer-the-next-generation-of-innoc4299606 https://news.cision.com/se/astrazeneca/r/astrazeneca-plans-to-invest--15-billion-in-china-through-2030-to-pioneer-the-next-generation-of-innoc4299606"  
[X Link](https://x.com/BioStocks/status/2016834832328777951)  2026-01-29T11:24Z 71.3K followers, [----] engagements


"$GUTS patients with above median GLP-1-associated weight loss experienced 70% less post-GLP-1 weight regain with Revita vs sham at [--] months. Topline 6-month pivotal data and potential FDA filing expected in 2H'26"  
[X Link](https://x.com/BioStocks/status/2016844855125700754)  2026-01-29T12:04Z 71.3K followers, [----] engagements


"$UNCY FDA Accepts Oxylanthanum Carbonate (OLC) NDA Resubmission. PDUFA 06/27/26"  
[X Link](https://x.com/BioStocks/status/2016845327475552692)  2026-01-29T12:06Z 71.3K followers, [----] engagements


"$GUTS requested FDA feedback on potentially reclassifying Revita under the De Novo pathway rather than a PMA. Expects FDA feedback regarding the potential for use of the De Novo pathway in Q2"  
[X Link](https://x.com/BioStocks/status/2016847050822856916)  2026-01-29T12:13Z 71.3K followers, 19.6K engagements


"$RVMD Doses First Patient in Clinical Trial Evaluating RMC-5127 a RAS(ON) G12V-Selective Inhibitor"  
[X Link](https://x.com/BioStocks/status/2016859408974713341)  2026-01-29T13:02Z 71.3K followers, [----] engagements


"$GUTS Anticipated Catalysts"  
[X Link](https://x.com/BioStocks/status/2016861359057625402)  2026-01-29T13:09Z 71.3K followers, [----] engagements


"$GUTS downgraded to Equalweight at Morgan Stanley. PT $2 from $8. Six-month results from Revita treatment in weight maintenance showed trends but fell short of expectations. MS believes that success in the pivotal study with data expected in 2H'26 remains possible"  
[X Link](https://x.com/BioStocks/status/2017022995399655788)  2026-01-29T23:52Z 71.3K followers, [----] engagements


"$COYA $11M private placement at $4.40/share"  
[X Link](https://x.com/BioStocks/status/2017221683082322206)  2026-01-30T13:01Z 71.3K followers, [----] engagements


"$IOBT retains Raymond James as the exclusive financial advisor to assist the company in the exploration of strategic alternatives. Announces a significant reduction in workforce $IOBT Announces Exploration of Strategic Alternatives Including Sale Wind-Down and Further Reduction in Workforce $IOBT Announces Exploration of Strategic Alternatives Including Sale Wind-Down and Further Reduction in Workforce"  
[X Link](https://x.com/BioStocks/status/2017223510003691602)  2026-01-30T13:08Z 71.3K followers, [----] engagements


"$RARE Resubmits BLA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)"  
[X Link](https://x.com/BioStocks/status/2017229327666933927)  2026-01-30T13:32Z 71.3K followers, [----] engagements


"De Novo regulatory pathway. $GUTS https://www.advamed.org/wp-content/uploads/2021/05/advamed_accel-regulatory_guides-de_novo.pdf $GUTS requested FDA feedback on potentially reclassifying Revita under the De Novo pathway rather than a PMA. Expects FDA feedback regarding the potential for use of the De Novo pathway in Q2 https://www.advamed.org/wp-content/uploads/2021/05/advamed_accel-regulatory_guides-de_novo.pdf $GUTS requested FDA feedback on potentially reclassifying Revita under the De Novo pathway rather than a PMA. Expects FDA feedback regarding the potential for use of the De Novo"  
[X Link](https://x.com/BioStocks/status/2017623909043142948)  2026-01-31T15:40Z 71.3K followers, 14.1K engagements


"$PRAX initiated with an Equal Weight at Wells Fargo. PT $282"  
[X Link](https://x.com/BioStocks/status/2018287741130203366)  2026-02-02T11:37Z 71.4K followers, [----] engagements


"$AQST FDA issues CRL Anaphylm. - Deficiencies limited to packaging and administration - Co believes it can rapidly resolve deficiencies and expects to resubmit as early as Q3"  
[X Link](https://x.com/BioStocks/status/2018293801756803559)  2026-02-02T12:01Z 71.4K followers, 36.6K engagements


"$EXEL NDA Accepted for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer. PDUFA 12/03/26"  
[X Link](https://x.com/BioStocks/status/2018323012865421712)  2026-02-02T13:57Z 71.3K followers, [----] engagements


"$RVMD PT raised to $122 at JPMorgan"  
[X Link](https://x.com/BioStocks/status/2018325150588903719)  2026-02-02T14:06Z 71.3K followers, [----] engagements


"$PFE Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing. $LLY $NVO Study demonstrated statistically significant weight reduction with up to 12.3% mean placebo-adjusted weight loss at wk [--] Weight loss continued after pre-planned switch from weekly to monthly dosing with no plateau observed at [--] wks https://www.businesswire.com/news/home/20260202566685/en/Pfizers-Ultra-Long-Acting-Injectable-GLP-1-RA-Shows-Robust-and-Continued-Weight-Loss-with-Monthly-Dosing-in-Phase-2b-Trial"  
[X Link](https://x.com/BioStocks/status/2018664453479260577)  2026-02-03T12:34Z 71.3K followers, [----] engagements


"$PRAX PT raised to $510 at Needham"  
[X Link](https://x.com/BioStocks/status/2019010814620119522)  2026-02-04T11:31Z 71.3K followers, [----] engagements


"$HOTH over the last several days investors have contacted the company re our exposure to digital assets such as Bitcoin Solana and Ethereum. Hoth holds no crypto assets and its maximum exposure never reached more than $350K over the last year. https://ir.hoththerapeutics.com/single-news-releases/storyId=5864616746764558 https://ir.hoththerapeutics.com/single-news-releases/storyId=5864616746764558"  
[X Link](https://x.com/BioStocks/status/2019402506816876760)  2026-02-05T13:27Z 71.3K followers, [----] engagements


"@Biomaven @A_May_MD https://www.nasdaq.com/press-release/novo-nordisk-issues-statement-illegal-mass-compounding-and-deceptive-advertising-hims https://www.nasdaq.com/press-release/novo-nordisk-issues-statement-illegal-mass-compounding-and-deceptive-advertising-hims"  
[X Link](https://x.com/BioStocks/status/2019562143620952548)  2026-02-06T00:01Z 71.3K followers, [---] engagements


"$NVO Wegovy pill in high demand in weeks since launch. $LLY $VKTX $HIMS Apprx [-----] prescriptions were being filled each week. More than [------] people in the U.S. are taking the new GLP-1 pill. https://www.nbcnews.com/health/health-news/170000-people-us-are-taking-wegovy-pill-novo-nordisk-says-rcna257395 https://www.nbcnews.com/health/health-news/170000-people-us-are-taking-wegovy-pill-novo-nordisk-says-rcna257395"  
[X Link](https://x.com/BioStocks/status/2020141962498601056)  2026-02-07T14:25Z 71.3K followers, 21.3K engagements


"$FDMT Completes Enrollment for 4FRONT-1 Phase [--] Clinical Trial of 4D-150 in Wet AMD Topline data from 4FRONT-1 expected in 1H'27"  
[X Link](https://x.com/BioStocks/status/2020845751270609396)  2026-02-09T13:02Z 71.3K followers, [----] engagements


"$NVO is taking $HIMS to court seeking a permanent ban on the sale of unapproved compounded versions of its blockbuster drugs. $LLY"  
[X Link](https://x.com/BioStocks/status/2020849254193856781)  2026-02-09T13:16Z 71.3K followers, [----] engagements


"$UPB Upstream Bio Reports Positive Top-Line Results from the Phase [--] VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps https://investors.upstreambio.com/news-releases/news-release-details/upstream-bio-reports-positive-top-line-results-phase-2-vibrant https://investors.upstreambio.com/news-releases/news-release-details/upstream-bio-reports-positive-top-line-results-phase-2-vibrant"  
[X Link](https://x.com/BioStocks/status/1962818438893572247)  2025-09-02T10:02Z 71.3K followers, [----] engagements


"Offerings priced - $RAPP $250M - 9.61M shares at $26/share $DNTH $251M - 6.48M shares at $33/share $AMLX $175M - 17.5M shares at $17/share"  
[X Link](https://x.com/BioStocks/status/1965716433243099405)  2025-09-10T09:58Z 71.3K followers, [----] engagements


"AI in Biotech Market to Reach $11.4 Billion by [----] $ABSI $RXRX $TEM $SDGR $NVDA $ABCL https://www.globenewswire.com/news-release/2025/10/24/3172929/0/en/AI-in-Biotechnology-Market-to-Reach-11-4-Billion-by-2030.html https://www.globenewswire.com/news-release/2025/10/24/3172929/0/en/AI-in-Biotechnology-Market-to-Reach-11-4-Billion-by-2030.html"  
[X Link](https://x.com/BioStocks/status/1982090344473772519)  2025-10-25T14:22Z 71.3K followers, [----] engagements


"$CBIO $185M PIPE. Forbion Fairmount Vestal Point Capital BVF Partners ADAR1 Balyasny Asset Management and Venrock Healthcare Capital https://investors.crescentbiopharma.com/news-releases/news-release-details/crescent-biopharma-announces-transformational-partnership-kelun https://investors.crescentbiopharma.com/news-releases/news-release-details/crescent-biopharma-announces-transformational-partnership-kelun"  
[X Link](https://x.com/BioStocks/status/1996544493261324562)  2025-12-04T11:37Z 71.3K followers, 11.3K engagements


"Indian Court Rejects $NVO's Injunction Plea Allows Dr. Reddy's to Manufacture and Export Generic Versions of Semaglutide. $RDY https://www.morningstar.com/news/dow-jones/202512042256/indian-court-allows-dr-reddys-to-produce-generic-versions-of-novo-nordisks-blockbuster-drugs https://www.morningstar.com/news/dow-jones/202512042256/indian-court-allows-dr-reddys-to-produce-generic-versions-of-novo-nordisks-blockbuster-drugs"  
[X Link](https://x.com/BioStocks/status/1996546564333126132)  2025-12-04T11:46Z 71.3K followers, [----] engagements


"$GPCR Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist Aleniglipron https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-access https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-access"  
[X Link](https://x.com/BioStocks/status/1998015453613154420)  2025-12-08T13:03Z 71.3K followers, 30.8K engagements


"$JBIO $45M PIPE at $14/share"  
[X Link](https://x.com/BioStocks/status/2000537912820044063)  2025-12-15T12:06Z 71.3K followers, [----] engagements


"$TYRA added to Best Ideas List at Wedbush. PT raised to $37"  
[X Link](https://x.com/BioStocks/status/2000889937336655927)  2025-12-16T11:25Z 71.3K followers, [----] engagements


"$SLGL following unblinding the data from the vehicle-controlled Phase 1b study did not show differentiation between SGT-210 and vehicle on the studys efficacy assessments"  
[X Link](https://x.com/BioStocks/status/2001261415001477352)  2025-12-17T12:01Z 71.3K followers, [----] engagements


"$AVIR Completes Patient Enrollment in North American Phase [--] Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus. Topline Results Data Mid-2026"  
[X Link](https://x.com/BioStocks/status/2003073580314288554)  2025-12-22T12:02Z 71.3K followers, [----] engagements


"$AGIO label including Boxed Warning. https://www.agios.com/prescribinginfoAqvesme.pdf https://www.agios.com/prescribinginfoAqvesme.pdf"  
[X Link](https://x.com/BioStocks/status/2003628380265336854)  2025-12-24T00:46Z 71.3K followers, [----] engagements


"$JNJ terminates JNJ-95475939 study in Atopic Dermatitis https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-the-phase-2b-duplex-ad-study https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-the-phase-2b-duplex-ad-study"  
[X Link](https://x.com/BioStocks/status/2004556958880403473)  2025-12-26T14:16Z 71.3K followers, 66.2K engagements


"$NMRA Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimers Disease Agitation https://ir.neumoratx.com/news-releases/news-release-details/neumora-therapeutics-announces-positive-results-nmra-511-phase https://ir.neumoratx.com/news-releases/news-release-details/neumora-therapeutics-announces-positive-results-nmra-511-phase"  
[X Link](https://x.com/BioStocks/status/2008139292883952017)  2026-01-05T11:31Z 71.3K followers, [----] engagements


"$GANX provided additional biomarker and clinical data from the Phase 1b clinical study of GT-02287 in people with Parkinsons disease with or without a GBA1 mutation that further supports the disease-modifying potential of GT-02287 https://ca.finance.yahoo.com/news/gain-therapeutics-highlights-biomarker-evidence-120000261.html https://ca.finance.yahoo.com/news/gain-therapeutics-highlights-biomarker-evidence-120000261.html"  
[X Link](https://x.com/BioStocks/status/2008511893145849909)  2026-01-06T12:12Z 71.3K followers, [----] engagements


"$TIL $TIL Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco $TIL Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco"  
[X Link](https://x.com/BioStocks/status/2008518873533083917)  2026-01-06T12:39Z 71.3K followers, [----] engagements


"$PRAX prices $575M offering. 2.21M shares at $260/share"  
[X Link](https://x.com/BioStocks/status/2008857169459036433)  2026-01-07T11:04Z 71.3K followers, [----] engagements


"$VERA FDA Grants Priority Review to BLA for Atacicept for Treatment of Adults with IgA Nephropathy. PDUFA 07/07/26"  
[X Link](https://x.com/BioStocks/status/2008879135393992709)  2026-01-07T12:31Z 71.3K followers, [----] engagements


"$VNDA receives FDA decision letter that HETLIOZ sNDA for Jet Lag Disorder cannot be approved in its current form"  
[X Link](https://x.com/BioStocks/status/2009235384681812278)  2026-01-08T12:07Z 71.3K followers, [----] engagements


"$AMLX Announces Nomination of AMX0318 as a Novel Long-Acting GLP-1 Receptor Antagonist Development Candidate Identified in Collaboration with Gubra A/S"  
[X Link](https://x.com/BioStocks/status/2009235535093731673)  2026-01-08T12:07Z 71.3K followers, [----] engagements


"$LXEO Announces Research Collaboration with $JNJ to Explore Targeted Cardiac Delivery of AAV Gene Therapy"  
[X Link](https://x.com/BioStocks/status/2009236379797213230)  2026-01-08T12:10Z 71.3K followers, [----] engagements


"#Biotech offerings priced - $PRAX $575M at $260/share $CRNX $350M at $45.95/share $ALMS $300M at $17/share $ARWR $200M at $64.50/share $DRUG $175M at $90/share $PHAT $130M at $16/share $1.73 Billion 💰💰 https://twitter.com/i/web/status/2009246537595924654 https://twitter.com/i/web/status/2009246537595924654"  
[X Link](https://x.com/BioStocks/status/2009246537595924654)  2026-01-08T12:51Z 71.3K followers, [----] engagements


"$IPSC $135M PIPE The financing is being led by new investor TCGX and includes participation from RA Capital Commodore Capital Deep Track Capital RTW Investments Venrock Healthcare Capital Partners and the T1D Fund"  
[X Link](https://x.com/BioStocks/status/2009250373999976769)  2026-01-08T13:06Z 71.3K followers, [----] engagements


"$ATHA Athira Pharma Announces Name Change to LeonaBio. New Ticker $LONA"  
[X Link](https://x.com/BioStocks/status/2009603123044852013)  2026-01-09T12:28Z 71.3K followers, [----] engagements


"$STOK updates timeline for Phase [--] EMPEROR study. Co now expects to complete enrollment of [---] patients in Q2'26 with a Phase [--] data readout in mid-2027. $BIIB https://investor.stoketherapeutics.com/news-releases/news-release-details/stoke-therapeutics-announces-updates-timelines-completion https://investor.stoketherapeutics.com/news-releases/news-release-details/stoke-therapeutics-announces-updates-timelines-completion"  
[X Link](https://x.com/BioStocks/status/2010496998475002301)  2026-01-11T23:40Z 71.3K followers, [----] engagements


"$BOLD to cease enrollment of the Phase 1/2 POTENTIATE trial in oncogene-amplified cancers"  
[X Link](https://x.com/BioStocks/status/2013585321326166142)  2026-01-20T12:12Z 71.3K followers, [----] engagements


"$IPSC PT raised from $2 to $4 at Piper. Century plans to submit an IND for CNTY-813 this year and report initial data in [----]. The firm estimates the Co now holds pro forma cash of $267M to fund operations into Q1'29"  
[X Link](https://x.com/BioStocks/status/2013593056058945549)  2026-01-20T12:42Z 71.3K followers, [----] engagements


"$OCUL Appoints David W. Robinson as Global Chief Commercial Officer. $MRK $REGN As VP of Sales and Marketing David successfully developed and executed the strategic plan to launch Regenerons first product to market EYLEA"  
[X Link](https://x.com/BioStocks/status/2013950223559660029)  2026-01-21T12:22Z 71.3K followers, [----] engagements


"$TARA to Present Updated Interim Data from Phase [--] ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium"  
[X Link](https://x.com/BioStocks/status/2014322751251656968)  2026-01-22T13:02Z 71.3K followers, [----] engagements


"$GDRX downgraded to Hold at Jefferies. PT $2.75"  
[X Link](https://x.com/BioStocks/status/2014333030991548487)  2026-01-22T13:43Z 71.3K followers, [----] engagements


"$UTHR Announces Positive Results from Phase [--] Study of miroliverELAP in Patients with Acute Liver Failure https://www.businesswire.com/news/home/20260126667812/en/United-Therapeutics-Announces-Positive-Results-from-Phase-1-Study-of-miroliverELAP-in-Patients-with-Acute-Liver-Failure https://www.businesswire.com/news/home/20260126667812/en/United-Therapeutics-Announces-Positive-Results-from-Phase-1-Study-of-miroliverELAP-in-Patients-with-Acute-Liver-Failure"  
[X Link](https://x.com/BioStocks/status/2015757060932063442)  2026-01-26T12:01Z 71.3K followers, [----] engagements


"$MRK intends to acquire a 10% equity stake in Eikon Therapeutics IPO. $EIKN"  
[X Link](https://x.com/BioStocks/status/2016668860426883243)  2026-01-29T00:24Z 71.3K followers, 36.1K engagements


"$GRAL Submits PMA for the Galleri Multi-Cancer Early Detection Test"  
[X Link](https://x.com/BioStocks/status/2017044211258835263)  2026-01-30T01:16Z 71.3K followers, [----] engagements


"$PCVX $550M offering priced at $50/share"  
[X Link](https://x.com/BioStocks/status/2017185865353621643)  2026-01-30T10:39Z 71.3K followers, [----] engagements


"$ALXO $150M offering 77M shares+warrants at $1.57/share"  
[X Link](https://x.com/BioStocks/status/2017229807746961638)  2026-01-30T13:33Z 71.3K followers, [----] engagements


"#Biotech Stocks Facing FDA Decision In February. $RGNX $VNDA $ETON $ASND $BMRN $XBI https://www.rttnews.com/slideshow/3925/biotech-stocks-facing-fda-decision-in-february-2026.aspxSlide=1 https://www.rttnews.com/slideshow/3925/biotech-stocks-facing-fda-decision-in-february-2026.aspxSlide=1"  
[X Link](https://x.com/BioStocks/status/2017968681750557174)  2026-02-01T14:30Z 71.3K followers, [----] engagements


"$WVE has regained full rights to WVE-006 a GalNAc-conjugated RNA editing oligonucleotide (AIMer) for alpha-1 antitrypsin deficiency (AATD) from $GSK Plans to engage FDA on potential accelerated approval pathway for WVE-006 with regulatory feedback anticipated mid-2026"  
[X Link](https://x.com/BioStocks/status/2018301410983497741)  2026-02-02T12:32Z 71.3K followers, [----] engagements


"$CVNA Carvanas entire business runs on a cycle of borrowed money. https://www.bloomberg.com/news/features/2026-02-01/carvana-growth-fueled-by-hot-used-car-market-meme-stocks-debtembedded-checkout=true https://www.bloomberg.com/news/features/2026-02-01/carvana-growth-fueled-by-hot-used-car-market-meme-stocks-debtembedded-checkout=true"  
[X Link](https://x.com/BioStocks/status/2018323921922118096)  2026-02-02T14:01Z 71.3K followers, [----] engagements


"$SRPT Announces Approval of Clinical Trial Application for SRP-1005 Its Investigational Treatment for Huntingtons Disease The first-in-human clinical study of SRP-1005 known as INSIGHTT is expected to begin in Q2"  
[X Link](https://x.com/BioStocks/status/2019041089529987153)  2026-02-04T13:31Z 71.3K followers, 22.3K engagements


"$EIKN Eikon Therapeutics 21.17M share IPO priced at $18/share. $MRK The company expects gross proceeds of $381M from the offering $MRK intends to acquire a 10% equity stake in Eikon Therapeutics IPO. $EIKN $MRK intends to acquire a 10% equity stake in Eikon Therapeutics IPO. $EIKN"  
[X Link](https://x.com/BioStocks/status/2019229261757051128)  2026-02-05T01:59Z 71.3K followers, 16.8K engagements


"$OCUL SOL-1 Phase [--] superiority trial results remain masked to date - SOL-1 data expected to be presented at the 49th Macula Society Annual Meeting - Plans to submit NDA for AXPAXLI in wet AMD based on SOL-1 [--] Week data - Completed randomization of [---] subjects in SOL-R Phase [--] non-inferiority trial in Dec. Timing of topline results accelerated and now anticipated in 1Q'27 https://twitter.com/i/web/status/2019381354232754325 https://twitter.com/i/web/status/2019381354232754325"  
[X Link](https://x.com/BioStocks/status/2019381354232754325)  2026-02-05T12:03Z 71.3K followers, 11.7K engagements


"$OCUL Q4 total net revenue $13.3M. 22% YoY FY'25 total net revenue $52M. 18% YoY Cash balance of $737M with expected runway into 2028"  
[X Link](https://x.com/BioStocks/status/2019382152530665792)  2026-02-05T12:06Z 71.3K followers, [----] engagements


"$BMY Q4 EPS $1.26 beats $1.11 Est. Sales $12.5B beat $12.2B Est Sees FY'26 Adj EPS $6.05-$6.35 vs $6.02 Est Sales $46B-$47.5B vs $44.1B Est"  
[X Link](https://x.com/BioStocks/status/2019383209537204321)  2026-02-05T12:10Z 71.3K followers, [----] engagements


"$HIMS Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month. $NVO $LLY https://www.businesswire.com/news/home/20260205680502/en/Hims-Hers-Expands-Personalized-Weight-Loss-Portfolio-with-Access-to-Compounded-Semaglutide-Pills-Starting-at-%2449Month https://www.businesswire.com/news/home/20260205680502/en/Hims-Hers-Expands-Personalized-Weight-Loss-Portfolio-with-Access-to-Compounded-Semaglutide-Pills-Starting-at-%2449Month"  
[X Link](https://x.com/BioStocks/status/2019413256151212358)  2026-02-05T14:10Z 71.3K followers, [----] engagements


"$EIKN $EIKN Eikon Therapeutics 21.17M share IPO priced at $18/share. $MRK The company expects gross proceeds of $381M from the offering $EIKN Eikon Therapeutics 21.17M share IPO priced at $18/share. $MRK The company expects gross proceeds of $381M from the offering"  
[X Link](https://x.com/BioStocks/status/2019564371928838471)  2026-02-06T00:10Z 71.3K followers, [----] engagements


"Best and worst #SuperBowl commercials of [----] Best: Google Super Bowl ad. $GOOG Worst: Coinbase. $COIN https://www.cbsnews.com/news/best-worst-super-bowl-commercials-2026/ https://www.cbsnews.com/news/best-worst-super-bowl-commercials-2026/"  
[X Link](https://x.com/BioStocks/status/2021014897971298572)  2026-02-10T00:14Z 71.3K followers, [----] engagements


"$INCY Q4 total net product revenue $1.22B and $4.3B for FY'25"  
[X Link](https://x.com/BioStocks/status/2021194229586817367)  2026-02-10T12:07Z 71.3K followers, [----] engagements


"$EVMN Announces Positive Topline Data from Phase 2a Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis. $NKTR $CRVS - 33% placebo-adjusted improvement in EASI at week [--] - 23% of EVO301 patients achieved IGA 0/1 at week [--] http://businesswire.com/news/home/20260210709064/en/ http://businesswire.com/news/home/20260210709064/en/"  
[X Link](https://x.com/BioStocks/status/2021201851216166940)  2026-02-10T12:37Z 71.3K followers, [----] engagements


"$EXEL in Q4 repurchased $264.5M of the cos stock at an average price of $43.17/share. Since March [----] Exelixis has repurchased a total of $2.16 billion of common stock retiring 76.7M shares at an average price of $28.14/share"  
[X Link](https://x.com/BioStocks/status/2021402240045731959)  2026-02-11T01:53Z 71.3K followers, [----] engagements


"$VKTX 16% $BBIO 18% $MCRB 25% PM movers. $XBI"  
[X Link](https://x.com/BioStocks/status/2021929395548532946)  2026-02-12T12:48Z 71.3K followers, [----] engagements


"$ALNY Q4 Adj. EPS $1.25 beats $1.17 Estimate Sales $1.09B miss $1.17B Estimate"  
[X Link](https://x.com/BioStocks/status/2021934412565455344)  2026-02-12T13:08Z 71.3K followers, [----] engagements


"$LLY builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision. $NVO $VKTX https://ca.finance.yahoo.com/news/eli-lilly-builds-1-5-202714274.html https://ca.finance.yahoo.com/news/eli-lilly-builds-1-5-202714274.html"  
[X Link](https://x.com/BioStocks/status/2022288333255082383)  2026-02-13T12:34Z 71.3K followers, [----] engagements


"$IMUX $400M PIPE. 30% PM - Initiates search for new CEO - Thor Nagel Principal at BVF Partners appointed to the Board BVF Partners Aberdeen Investments Avidity Partners Coastlands Capital EcoR1 Janus Henderson OrbiMed RA Capital TCGX Trails Edge Capital Vivo Capital"  
[X Link](https://x.com/BioStocks/status/2022291279225229644)  2026-02-13T12:46Z 71.3K followers, [----] engagements


"$HIMS Shorts Up $1.3 Billion This Year. $NVO $LLY https://www.bloomberg.com/news/articles/2026-02-13/hims-hers-shorts-up-1-3-billion-this-year-on-legal-riskembedded-checkout=true https://www.bloomberg.com/news/articles/2026-02-13/hims-hers-shorts-up-1-3-billion-this-year-on-legal-riskembedded-checkout=true"  
[X Link](https://x.com/BioStocks/status/2022679426509705489)  2026-02-14T14:28Z 71.3K followers, [----] engagements


"Just realized I celebrate my 15th Twitterversary this month. Back then I never imagined this app would become a second home. What started as a place to share ideas has grown into so much more. This platform has allowed me to share biotech insights bounce ideas and learn from the sharpest minds. But the best part The connections. Some of you have been here since the early days and others have joined along the waybut every interaction has pushed me to grow. This is an incredible community: thank you for the support ideas and conversations. 🫶"  
[X Link](https://x.com/BioStocks/status/1893731872108069305)  2025-02-23T18:37Z 71.3K followers, 107.3K engagements


"$ANEB Following the announcement of a going-private transaction the Company received inbound interest from potential financial and strategic partners. The Board will review all strategic alternatives available to the Company https://www.businesswire.com/news/home/20250912026618/en/Anebulo-Pharmaceuticals-Announces-Update-on-Going-Private-Transaction-and-Strategic-Alternatives https://www.businesswire.com/news/home/20250912026618/en/Anebulo-Pharmaceuticals-Announces-Update-on-Going-Private-Transaction-and-Strategic-Alternatives"  
[X Link](https://x.com/BioStocks/status/1966465532233724174)  2025-09-12T11:34Z 71.3K followers, [----] engagements


"$CYBN $175M PIPE Venrock Partners OrbiMed Point72 Deep Track Capital Acorn Bioventures Spruce Street Capital Squadron Capital Adage Capital Boxer Capital ADAR1 Capital Management Stonepine Capital Management Pivotal Bioventure Partners Ally Bridge Group"  
[X Link](https://x.com/BioStocks/status/1983142489205649686)  2025-10-28T12:03Z 71.3K followers, 22.1K engagements


"$QURE believes that the FDA currently no longer agrees that data from the Phase I/II studies of AMT-130 in comparison to an external control may be adequate to provide the primary evidence in support of a BLA submission"  
[X Link](https://x.com/BioStocks/status/1985318121918312878)  2025-11-03T12:08Z 71.3K followers, 82K engagements


"$ADAG Announces FDA Fast Track Designation for Muzastotug (ADG126)"  
[X Link](https://x.com/BioStocks/status/2000899029094338898)  2025-12-16T12:01Z 71.3K followers, [----] engagements


"$BIVI Completes Enrollment in Phase [--] SUNRISE-PD Trial in Early Parkinsons Disease. - Topline Data from the SUNRISE-PD Trial Expected in 1H'26"  
[X Link](https://x.com/BioStocks/status/2009249887041323059)  2026-01-08T13:04Z 71.3K followers, [----] engagements


"$LQDA - Estimated YUTREPIA Q4 net product sales $90.1M and $148.3M for FY'25 - Received more than [----] unique patient prescriptions since launch in June'25 - Generated more than $30M of positive cash flow in Q4'25 - Cash and cash equivalents $191M $UTHR"  
[X Link](https://x.com/BioStocks/status/2009589246299197533)  2026-01-09T11:33Z 71.3K followers, 12.4K engagements


"$LXEO Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy https://ir.lexeotx.com/news-releases/news-release-details/lexeo-therapeutics-announces-positive-interim-phase-iii-data https://ir.lexeotx.com/news-releases/news-release-details/lexeo-therapeutics-announces-positive-interim-phase-iii-data"  
[X Link](https://x.com/BioStocks/status/2010684044111954357)  2026-01-12T12:03Z 71.3K followers, 12.1K engagements


"FDA delays drug reviews in the new National Priority Voucher program after safety and efficacy concerns. $IRON $SNY $LLY https://ca.news.yahoo.com/exclusive-us-fda-delays-two-110222936.html https://ca.news.yahoo.com/exclusive-us-fda-delays-two-110222936.html"  
[X Link](https://x.com/BioStocks/status/2011758382903148881)  2026-01-15T11:12Z 71.3K followers, 11.5K engagements


"$SNY to pursue global regulatory submissions for Amlitelimab in AD despite mixed pivotal readouts. $REGN $CRVS $NKTR https://firstwordpharma.com/story/7078556 https://firstwordpharma.com/story/7078556"  
[X Link](https://x.com/BioStocks/status/2014657690039923085)  2026-01-23T11:13Z 71.3K followers, 10.7K engagements


"$GUTS Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita After GLP-1 Discontinuation https://ir.fractyl.com/news-releases/news-release-details/fractyl-health-announces-compelling-6-month-randomized-remain-1 https://ir.fractyl.com/news-releases/news-release-details/fractyl-health-announces-compelling-6-month-randomized-remain-1"  
[X Link](https://x.com/BioStocks/status/2016844264785772855)  2026-01-29T12:01Z 71.3K followers, [----] engagements


"$AZN collaboration agreement with China's CSPC Pharma to advance the development of multiple next-generation therapies for obesity and type [--] diabetes. CSPC to receive $1.2 billion upfront https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-agrees-obesity-and-t2d-deal-with-cspc.html https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-agrees-obesity-and-t2d-deal-with-cspc.html"  
[X Link](https://x.com/BioStocks/status/2017208761073438808)  2026-01-30T12:10Z 71.3K followers, [----] engagements


"Merger Arbs Investors See Wide Open Deal Window With #Biotech Top of List $RVMD is seen as the top takeover target with $ABVX also mentioned frequently. Both firms have been reported to receive interest from several potential suitors. $XBI https://www.bloomberg.com/news/articles/2026-01-26/revolution-medicines-abivax-rvmd-abvx-seen-as-top-m-a-targets https://www.bloomberg.com/news/articles/2026-01-26/revolution-medicines-abivax-rvmd-abvx-seen-as-top-m-a-targets"  
[X Link](https://x.com/BioStocks/status/2017598491489669637)  2026-01-31T13:59Z 71.3K followers, [----] engagements


"$OCUL topline results of the SOL-1 Phase [--] superiority clinical trial of AXPAXLI for the treatment of wet AMD are expected to be presented at the 49th Macula Society Annual Meeting taking place between Feb 25th 28th $OCUL SOL-1 Phase [--] superiority trial results remain masked to date - SOL-1 data expected to be presented at the 49th Macula Society Annual Meeting - Plans to submit NDA for AXPAXLI in wet AMD based on SOL-1 [--] Week data - Completed randomization of [---] subjects in SOL-R Phase [--] $OCUL SOL-1 Phase [--] superiority trial results remain masked to date - SOL-1 data expected to be"  
[X Link](https://x.com/BioStocks/status/2019384115842445762)  2026-02-05T12:14Z 71.3K followers, [----] engagements


"$BIIB Q4 total revenue $2.3B. FY'25 total rev $9.9B LEQEMBI Q4 sales $134M. 54% YoY Spinraza revenue 15% to $356.2M Sees FY'26 adj EPS $15.25-$16.25 vs $14.92 Est. Expects rev to decline by mid-single digits Cash and equivalents $4.2B with $6.3B in total debt"  
[X Link](https://x.com/BioStocks/status/2019732902221856915)  2026-02-06T11:20Z 71.3K followers, [----] engagements


"$TERN initiated with an Outperform at Leerink. PT $58"  
[X Link](https://x.com/BioStocks/status/2020844568556757390)  2026-02-09T12:57Z 71.3K followers, [----] engagements


"$MRNA Receives Refusal-to-File Letter for Its Investigational Seasonal Influenza Vaccine mRNA-1010 https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/moderna-receives-refusal-to-file-letter-from-the-u.s.-food-and-drug-a-1135749 https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/moderna-receives-refusal-to-file-letter-from-the-u.s.-food-and-drug-a-1135749"  
[X Link](https://x.com/BioStocks/status/2021372583032316062)  2026-02-10T23:55Z 71.3K followers, 10.5K engagements


"The first highly anticipated GLP-1 pill is here but physicians aren't sure it has the staying power of the injections. $NVO $LLY $VKTX https://www.marketwatch.com/story/taking-the-new-wegovy-pill-every-day-is-really-complicated-will-patients-stick-with-it-280d24f6 https://www.marketwatch.com/story/taking-the-new-wegovy-pill-every-day-is-really-complicated-will-patients-stick-with-it-280d24f6"  
[X Link](https://x.com/BioStocks/status/2021714110636011635)  2026-02-11T22:33Z 71.3K followers, 14.7K engagements


"$MCRB is pausing additional investment in the SER-155 (allo-HSCT) program and will shift its operational focus to high-value earlier-stage pipeline programs while continuing to seek funding for the SER-155 Phase [--] study"  
[X Link](https://x.com/BioStocks/status/2021918598826967147)  2026-02-12T12:05Z 71.3K followers, [----] engagements


"$BBIO Reports Positive Phase [--] Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia. - PROPEL [--] successfully met the primary endpoint of change from baseline in AHV at Week [--] (p0.0001)"  
[X Link](https://x.com/BioStocks/status/2021925016888025489)  2026-02-12T12:31Z 71.3K followers, [----] engagements


"$BBIO given the strength of these data BridgeBio plans to accelerate the development of oral infigratinib in hypochondroplasia and is enrolling the observational run-in for the Phase [--] trial - NDA and MAA submissions planned in 2H'26 for achondroplasia $BBIO Reports Positive Phase [--] Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia. - PROPEL [--] successfully met the primary endpoint of change from baseline in AHV at Week [--] (p0.0001) $BBIO Reports Positive Phase [--] Topline Results for Oral Infigratinib with the"  
[X Link](https://x.com/BioStocks/status/2021925551582462335)  2026-02-12T12:33Z 71.3K followers, [----] engagements


"$BBIO Primary endpoint: Change from baseline in annualized height velocity (AHV) superior to placebo with an LS mean treatment difference of +1.74 cm/year (p0.0001) and a mean treatment difference of +2.10 cm/year - No discontinuations related to study drug - No SAE's related to study drug - [--] cases (4%) of hyperphosphatemia all mild transient asymptomatic and not requiring dose reductions or discontinuations https://twitter.com/i/web/status/2021926231424336087 https://twitter.com/i/web/status/2021926231424336087"  
[X Link](https://x.com/BioStocks/status/2021926231424336087)  2026-02-12T12:35Z 71.3K followers, [----] engagements


"$EVMN $125M private placement at $27.88/share"  
[X Link](https://x.com/BioStocks/status/2022128252522012677)  2026-02-13T01:58Z 71.3K followers, [----] engagements


"$NVO is aiming to capture around [--] million new patients when Medicare starts covering obesity treatments. $LLY $VKTX https://www.cnbc.com/2026/02/11/novo-nordisk-ceo-medicare-coverage-opens-15-million-patient-opportunity.html https://www.cnbc.com/2026/02/11/novo-nordisk-ceo-medicare-coverage-opens-15-million-patient-opportunity.html"  
[X Link](https://x.com/BioStocks/status/2022695829866197019)  2026-02-14T15:34Z 71.3K followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing